NO2753646T3 - - Google Patents
Info
- Publication number
- NO2753646T3 NO2753646T3 NO12761786A NO12761786A NO2753646T3 NO 2753646 T3 NO2753646 T3 NO 2753646T3 NO 12761786 A NO12761786 A NO 12761786A NO 12761786 A NO12761786 A NO 12761786A NO 2753646 T3 NO2753646 T3 NO 2753646T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1115280.8A GB201115280D0 (en) | 2011-09-05 | 2011-09-05 | Antibodies, uses and methods |
| PCT/GB2012/052179 WO2013034904A1 (en) | 2011-09-05 | 2012-09-05 | Anti-cd40 antibodies, uses and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2753646T3 true NO2753646T3 (he) | 2018-04-21 |
Family
ID=44882205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO12761786A NO2753646T3 (he) | 2011-09-05 | 2012-09-05 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9676862B2 (he) |
| EP (2) | EP3323834B1 (he) |
| JP (1) | JP6324891B2 (he) |
| KR (1) | KR102029946B1 (he) |
| CN (1) | CN103930442B (he) |
| AU (1) | AU2012306071B2 (he) |
| CA (1) | CA2860406C (he) |
| CY (1) | CY1119925T1 (he) |
| DK (2) | DK3323834T3 (he) |
| ES (2) | ES2967316T3 (he) |
| GB (1) | GB201115280D0 (he) |
| HR (1) | HRP20180269T1 (he) |
| HU (1) | HUE036538T2 (he) |
| LT (1) | LT2753646T (he) |
| NO (1) | NO2753646T3 (he) |
| PL (1) | PL2753646T3 (he) |
| PT (1) | PT2753646T (he) |
| RS (1) | RS56868B1 (he) |
| RU (1) | RU2649055C2 (he) |
| SI (1) | SI2753646T1 (he) |
| WO (1) | WO2013034904A1 (he) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| EP3936137A1 (en) | 2013-02-07 | 2022-01-12 | The General Hospital Corporation | Methods for expansion or depletion of t-regulatory cells |
| CR20170096A (es) * | 2014-08-12 | 2017-06-15 | Alligator Bioscience Ab | Tratamientos conjuntos con anticuerpos anti cd40 |
| ES2806500T3 (es) | 2015-01-20 | 2021-02-17 | Igm Biosciences Inc | Moléculas de unión al receptor de la superfamilia de TNF (factor de necrosis tumoral) y usos de las mismas |
| LT3283527T (lt) | 2015-04-13 | 2021-03-25 | Five Prime Therapeutics, Inc. | Kompleksinė terapija vėžio gydymui |
| WO2016187068A1 (en) * | 2015-05-15 | 2016-11-24 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| MX2017016844A (es) | 2015-07-16 | 2018-08-15 | Biokine Therapeutics Ltd | Composiciones y procedimientos para tratar cancer. |
| CN108368510B (zh) * | 2015-09-30 | 2023-09-01 | 詹森生物科技公司 | 特异性结合人cd40的激动性抗体和使用方法 |
| EP3370768B9 (en) | 2015-11-03 | 2022-03-16 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
| CN116715767A (zh) | 2016-05-13 | 2023-09-08 | 综合医院公司 | 拮抗性抗肿瘤坏死因子受体超家族抗体 |
| US10519243B2 (en) * | 2016-05-27 | 2019-12-31 | Abbvie Biotherapeutics Inc. | Anti-CD40 antibodies |
| EP3471754A1 (en) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1 antibodies |
| AU2017308734A1 (en) | 2016-08-12 | 2019-02-14 | Janssen Biotech, Inc. | Fc engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them |
| EP3497120A1 (en) | 2016-08-12 | 2019-06-19 | Janssen Biotech, Inc. | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions |
| GB201619652D0 (en) | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel polypeptides |
| KR20190095941A (ko) | 2016-12-19 | 2019-08-16 | 그렌마크 파머수티칼스 에스. 아. | 신규 tnfr 효능제 및 이의 용도 |
| WO2018160917A1 (en) | 2017-03-03 | 2018-09-07 | Janssen Biotech, Inc. | Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer |
| BR112019025048A2 (pt) | 2017-06-01 | 2020-06-30 | Jiangsu Hengrui Medicine Co., Ltd. | anticorpo anti-cd40, fragmento de ligação ao antígeno do mesmo, e uso médico dos mesmos |
| CN111225924B (zh) | 2017-09-19 | 2023-10-10 | Mab发现股份有限公司 | 激动性cd40抗体 |
| US11976123B2 (en) | 2018-04-20 | 2024-05-07 | Lyvgen Biopharma Holdings Limited | Anti-CD40 antibodies and uses thereof |
| US20210251994A1 (en) | 2018-06-15 | 2021-08-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| CN116178544A (zh) * | 2018-09-28 | 2023-05-30 | 礼进生物医药科技（上海）有限公司 | 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途 |
| MX2021005823A (es) | 2018-11-30 | 2021-07-15 | Jiangsu Hengrui Medicine Co | Anticuerpo anti-cd40, fragmento de union a antigeno y uso farmaceutico del mismo. |
| EP3939998A4 (en) | 2018-11-30 | 2022-08-10 | Jiangsu Hengrui Medicine Co., Ltd. | PHARMACEUTICAL COMPOSITION WITH CD40 ANTIBODY AND USE THEREOF |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| MA56027A (fr) | 2019-05-28 | 2022-04-06 | Janssen Biotech Inc | Procédé de fourniture d'une administration sûre d'un anticorps anti-cd40 |
| JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
| WO2021140222A1 (en) | 2020-01-10 | 2021-07-15 | Symphogen A/S | Anti-cd40 antibodies and compositions |
| GB202004677D0 (en) * | 2020-03-31 | 2020-05-13 | Alligator Bioscience Ab | Methods and compositions |
| JP2023532339A (ja) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用 |
| CA3214085A1 (en) | 2021-03-31 | 2022-10-06 | Darby Rye Schmidt | Thanotransmission polypeptides and their use in treating cancer |
| AU2022257908A1 (en) * | 2021-04-15 | 2023-11-30 | Icure Bnp Co., Ltd. | Cell-penetrating peptide, anti-cancer peptide, and pharmaceutical composition for preventing or treating cancer, comprising same |
| BR112023026111A2 (pt) * | 2021-06-28 | 2024-03-05 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo |
| EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2023079101A2 (en) * | 2021-11-05 | 2023-05-11 | Alligator Bioscience Ab | Novel polypeptides |
| WO2023247050A1 (en) * | 2022-06-23 | 2023-12-28 | Alligator Bioscience Ab | Combination therapies |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| NZ192465A (en) | 1978-12-22 | 1983-09-30 | Biogen Nv | Recombinant dna molecule comprising gene coding for polypeptide displaying hbv (hepatitis b virus) antigenicity usesthereof |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4348376A (en) | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US5168053A (en) | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
| GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
| US5149796A (en) | 1989-08-31 | 1992-09-22 | City Of Hope | Chimeric DNA-RNA catalytic sequences |
| US5643872A (en) | 1989-10-23 | 1997-07-01 | Smithkline Beecham Corporation | Cyclic anti-aggregatory peptides |
| US5180818A (en) | 1990-03-21 | 1993-01-19 | The University Of Colorado Foundation, Inc. | Site specific cleavage of single-stranded dna |
| GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
| US6008058A (en) | 1993-06-18 | 1999-12-28 | University Of Louisville | Cyclic peptide mixtures via side chain or backbone attachment and solid phase synthesis |
| WO1996006641A1 (en) | 1994-08-29 | 1996-03-07 | Prizm Pharmaceuticals, Inc. | Conjugates of vascular endothelial growth factor with targeted agents |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| IL135578A0 (en) * | 1997-10-29 | 2001-05-20 | Genzyme Corp | Compositions and methods for treating lysosomal storage disease |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| US6946129B1 (en) * | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| WO2001083755A2 (en) * | 2000-04-28 | 2001-11-08 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
| US6958213B2 (en) * | 2000-12-12 | 2005-10-25 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function |
| ES2244670T5 (es) | 2000-12-12 | 2012-08-02 | Alligator Bioscience Ab | Un método para una evolución molecular in vitro de una función proteínica |
| PT1391464E (pt) | 2001-04-27 | 2007-11-15 | Kirin Pharma Kk | Anticorpo monoclonal anti-cd40 |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| WO2003097834A2 (en) | 2002-05-17 | 2003-11-27 | Alligator Bioscience Ab | A method for in vitro molecular evolution of protein function |
| CN101014386A (zh) * | 2004-04-27 | 2007-08-08 | 诺华疫苗和诊断公司 | 拮抗性抗－cd40单克隆抗体及其使用方法 |
| RU2407544C2 (ru) * | 2005-05-26 | 2010-12-27 | Сиэтл Дженетикс, Инк. | Гуманизированные анти-cd40-антитела и способы их применения |
| WO2009094391A1 (en) | 2008-01-23 | 2009-07-30 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
-
2011
- 2011-09-05 GB GBGB1115280.8A patent/GB201115280D0/en not_active Ceased
-
2012
- 2012-09-05 SI SI201231140T patent/SI2753646T1/en unknown
- 2012-09-05 DK DK17195987.7T patent/DK3323834T3/da active
- 2012-09-05 HU HUE12761786A patent/HUE036538T2/hu unknown
- 2012-09-05 RU RU2014113304A patent/RU2649055C2/ru active
- 2012-09-05 CA CA2860406A patent/CA2860406C/en active Active
- 2012-09-05 JP JP2014527743A patent/JP6324891B2/ja active Active
- 2012-09-05 LT LTEP12761786.8T patent/LT2753646T/lt unknown
- 2012-09-05 EP EP17195987.7A patent/EP3323834B1/en active Active
- 2012-09-05 NO NO12761786A patent/NO2753646T3/no unknown
- 2012-09-05 PL PL12761786T patent/PL2753646T3/pl unknown
- 2012-09-05 RS RS20180200A patent/RS56868B1/sr unknown
- 2012-09-05 EP EP12761786.8A patent/EP2753646B1/en active Active
- 2012-09-05 CN CN201280054090.1A patent/CN103930442B/zh active Active
- 2012-09-05 WO PCT/GB2012/052179 patent/WO2013034904A1/en active Application Filing
- 2012-09-05 PT PT127617868T patent/PT2753646T/pt unknown
- 2012-09-05 AU AU2012306071A patent/AU2012306071B2/en active Active
- 2012-09-05 US US14/342,141 patent/US9676862B2/en active Active
- 2012-09-05 DK DK12761786.8T patent/DK2753646T3/en active
- 2012-09-05 KR KR1020147008695A patent/KR102029946B1/ko active IP Right Grant
- 2012-09-05 ES ES17195987T patent/ES2967316T3/es active Active
- 2012-09-05 ES ES12761786.8T patent/ES2658157T3/es active Active
-
2017
- 2017-05-08 US US15/588,919 patent/US10640567B2/en active Active
-
2018
- 2018-02-09 CY CY20181100161T patent/CY1119925T1/el unknown
- 2018-02-13 HR HRP20180269TT patent/HRP20180269T1/hr unknown